Why Europe still has no MAUDE equivalent — the transparency gap and what to do about it

Europe lacks a single, searchable public database like the FDA’s MAUDE, and that absence shapes how manufacturers, clinicians, and patients experience device safety information. I’ve spent the last five years managing vigilance reports, PSURs, and EUDAMED submissions for Class IIa/IIb devices; the result is a practical appreciation for why the gap exists — and what manufacturers can reasonably do while the system remains fragmented.

The gap in plain terms

MAUDE is a central, public adverse-event repository. In the EU we do have strong legal frameworks for vigilance and post-market surveillance — see Chapter VII of MDR 2017/745 — but the data flows are distributed:

• Manufacturers report serious incidents and FSCA (field safety corrective actions) to national competent authorities (NCAs), not to a single public portal.
• NCAs operate different IT systems, publication policies, and languages.
• EUDAMED was meant to centralise data, but its rollout has been phased and public access remains constrained in places.

In practice this means an interested clinician or hospital procurement officer cannot reliably query “what problems have been reported for device X” across the EU the way they can in the US.

Why there isn’t a MAUDE-equivalent (practical reasons)

To be fair, the absence isn’t solely bureaucratic laziness. Several concrete factors combine:

• Fragmented legal responsibilities: Member States retain core vigilance tasks. Reporting goes to NCAs and then — depending on the event — to other Member States, the Commission, and economic operators. Different organisations, different systems.
• Phased IT implementation: EUDAMED was designed to centralise identifiers, certificates, vigilance, and market surveillance data. Its modules were delivered incrementally; adoption and public-facing functionality vary.
• Confidentiality and commercial sensitivity: Manufacturers and notified bodies legitimately argue that releasing granular reports can reveal proprietary designs, supplier details, or confidential corrective actions. Those concerns influence what NCAs publish.
• Heterogeneous publication policies: Some NCAs publish FSCA notices and summaries; others publish less. Language differences and redaction practices further limit utility.
• Resource constraints: Smaller NCAs or national IT projects may lack the budget or staff to operate public dashboards and to normalise multilingual reports into a single, searchable format.

What this looks like day-to-day

When an investigator calls asking whether our device has had X-type failures, the workflow is rarely simple:

• Check internal vigilance log and PSUR summaries (we have them).
• Pull FSCA notices on our website and any communications to distributors/clinicians.
• Search NCA websites manually for public FSN (field safety notice) uploads in a handful of languages.
• Rely on notified-body feedback only if the issue touched conformity assessment — which is often not the case.

This manual triage wastes time and creates inconsistency in what external stakeholders hear.

Short-term manufacturer tactics that actually survive audits

Until a single, public EU database exists in practice, manufacturers can reduce opacity for users and strengthen regulatory posture. Practical steps I use:

• Publish FSN/FSCA summaries on your website, in English and the major national languages of your markets.
• Maintain a public-facing vigilance summary for each device family: a short timeline of significant incidents and actions (redacted where needed).
• Link clinical PMCF summaries or synopses to product pages — PSURs themselves are not public, but an executive summary is useful and audit-friendly.
• Use your eQMS to create connected workflows: link vigilance reports to CAPA, change control, risk assessment, and customer communications so you can produce consolidated narratives quickly for NCAs and clinicians.
• When possible, coordinate with distributors and hospitals to push FSNs to users rather than relying on NCA publication alone.

These are low-tech, high-value measures: they improve transparency without exposing proprietary process details.

Why transparency matters beyond optics

Lack of central visibility isn’t just inconvenient. It affects patient safety and market surveillance:

• Duplicate reports across Member States can be missed as signals if nobody aggregates them.
• Clinicians may reassign blame to devices prematurely without seeing manufacturer mitigations.
• Recalls or mitigations can be delayed simply because stakeholders are not aware of the same evidence.

A clearer public picture reduces unnecessary alarm and helps regulators and manufacturers prioritise real risks.

Where sensible compromise could live

A workable European model need not mirror MAUDE exactly. Practical design choices:

• Public executive summaries only (structured, anonymised) rather than full incident narratives containing supplier names or internal corrective plans.
• Strong UDI/Device Identification in EUDAMED combined with standardised taxonomy for incidents, to allow signal detection without revealing commercial details.
• A staged, searchable FSN register for devices of highest risk (implantables, class III) while lower-risk devices remain aggregated.

These balance transparency and commercial confidentiality — and they align with MDR’s push for public-facing summaries for higher-risk devices.

Final practical note for small manufacturers

If your notified-body audit is in three months, focus on traceability: can you pull a thread from a single incident to the final FSN, CAPA, and PMCF action? An eQMS with connected workflow (traceability, automated CAPAs, AI-assisted impact analysis where you trust it) will save you hours in evidence-gathering and produce consistent public-facing summaries faster.

To be fair, the EU’s approach is cautious for good reasons. But in five years of dealing with vigilance across multiple Member States, I’ve seen how opacity adds friction to both safety and compliance.

What small change would make vigilance data meaningfully easier for you to act on — a central searchable index, standardised FSN templates, or something else?